GlassScriptPhysician profile
Christopher Scot Johnson
NPI 1679205744
$2,224.09
in general payments reported to CMS, 2019-2025
22 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $658 · 2024: $830 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $512.23 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $308.90 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $300.94 | 2023-2025 | |
| Dexcom, INC. | $271.06 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $162.49 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $122.35 | 2023-2025 | |
| Glaxosmithkline, LLC. | $80.51 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $74.25 | 2023-2025 | Freestyle Libre 3, Eterna |
| Phathom Pharmaceuticals, INC. | $63.80 | 2024-2025 | Voquezna |
| Verona Pharma, INC. | $43.51 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.96 | 2023-2025 | Caplyta |
| Organon LLC | $36.96 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.08 | 2023 | |
| Astellas Pharma US INC | $32.93 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $21.31 | 2023 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.06 | 2023 | |
| Edwards Lifesciences Corporation | $18.00 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mylan Specialty L.P. | $17.76 | 2023 | Yupelri |
| Dynavax Technologies Corporation | $17.28 | 2024 | Heplisav-B |
| Genzyme Corporation | $16.16 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.43 | 2024 | Quviviq |
| Exact Sciences Corporation | $13.12 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.